JP2023530335A5 - - Google Patents

Info

Publication number
JP2023530335A5
JP2023530335A5 JP2022577390A JP2022577390A JP2023530335A5 JP 2023530335 A5 JP2023530335 A5 JP 2023530335A5 JP 2022577390 A JP2022577390 A JP 2022577390A JP 2022577390 A JP2022577390 A JP 2022577390A JP 2023530335 A5 JP2023530335 A5 JP 2023530335A5
Authority
JP
Japan
Prior art keywords
relaxin
section
chain
heterodimer fusion
heterodimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022577390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530335A (ja
JP7797423B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/066309 external-priority patent/WO2021255127A1/en
Publication of JP2023530335A publication Critical patent/JP2023530335A/ja
Publication of JP2023530335A5 publication Critical patent/JP2023530335A5/ja
Priority to JP2025279747A priority Critical patent/JP2026053559A/ja
Application granted granted Critical
Publication of JP7797423B2 publication Critical patent/JP7797423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022577390A 2020-06-17 2021-06-16 ヘテロ二量体リラキシン融合物及びその使用 Active JP7797423B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279747A JP2026053559A (ja) 2020-06-17 2025-12-24 ヘテロ二量体リラキシン融合物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
US63/040,250 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279747A Division JP2026053559A (ja) 2020-06-17 2025-12-24 ヘテロ二量体リラキシン融合物及びその使用

Publications (3)

Publication Number Publication Date
JP2023530335A JP2023530335A (ja) 2023-07-14
JP2023530335A5 true JP2023530335A5 (cg-RX-API-DMAC7.html) 2024-09-19
JP7797423B2 JP7797423B2 (ja) 2026-01-13

Family

ID=76584509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577390A Active JP7797423B2 (ja) 2020-06-17 2021-06-16 ヘテロ二量体リラキシン融合物及びその使用
JP2025279747A Pending JP2026053559A (ja) 2020-06-17 2025-12-24 ヘテロ二量体リラキシン融合物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279747A Pending JP2026053559A (ja) 2020-06-17 2025-12-24 ヘテロ二量体リラキシン融合物及びその使用

Country Status (17)

Country Link
US (3) US11795205B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168434A1 (cg-RX-API-DMAC7.html)
JP (2) JP7797423B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024994A (cg-RX-API-DMAC7.html)
CN (1) CN115916813B (cg-RX-API-DMAC7.html)
AR (1) AR125007A1 (cg-RX-API-DMAC7.html)
AU (3) AU2021290997C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025019A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186143A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003578A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000038A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230015A (cg-RX-API-DMAC7.html)
EC (1) ECSP23002960A (cg-RX-API-DMAC7.html)
IL (1) IL298786A (cg-RX-API-DMAC7.html)
MX (1) MX2022016340A (cg-RX-API-DMAC7.html)
TW (1) TWI899263B (cg-RX-API-DMAC7.html)
WO (1) WO2021255127A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
JP2025517100A (ja) 2022-05-07 2025-06-03 北京拓界生物医薬科技有限公司 リラキシン又は類似体の融合タンパク質及びその医薬的使用
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
IL321288A (en) 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers
WO2024184206A1 (en) 2023-03-03 2024-09-12 Astrazeneca Ab Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
DK3107938T3 (da) * 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
US11161891B2 (en) * 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
US20250011432A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
TWI648401B (zh) 生長分化因子15(gdf-15)構築體
US5767260A (en) Antigen-binding fusion proteins
JP2023085476A5 (cg-RX-API-DMAC7.html)
JP2017538395A5 (cg-RX-API-DMAC7.html)
JP2020196744A5 (cg-RX-API-DMAC7.html)
JP2023518434A5 (cg-RX-API-DMAC7.html)
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
CN107001468A (zh) Cd3结合结构域
JP2016510755A5 (cg-RX-API-DMAC7.html)
JP2021534220A5 (cg-RX-API-DMAC7.html)
CN118121696A (zh) 靶向骨的抗体
JP2024539139A5 (cg-RX-API-DMAC7.html)
JP2024546877A5 (cg-RX-API-DMAC7.html)
JP7676316B2 (ja) Hiv感染症の処置のためのクロスオーバー二重可変ドメイン(codv)フォーマットを使用した三重特異性および/または三価結合性タンパク質
JP2023554119A5 (cg-RX-API-DMAC7.html)
JP2025124718A5 (cg-RX-API-DMAC7.html)
CA3168444A1 (en) Bispecific gd2 and b7h2 binding molecules and methods of use
AR125007A1 (es) Fusiones heterodiméricas de relaxina y usos de las mismas
JP2022545234A (ja) Cd3とcd20を標的とする二重特異性抗体及びその使用
JP2024546129A5 (cg-RX-API-DMAC7.html)
JP2025524899A (ja) メソテリン結合タンパク質及びその使用
JP2024534118A (ja) 抗her2抗体及びその使用方法
US20240392035A1 (en) Engineered anti-her2 bispecific proteins